Drug Profile
Cefuroxime sodium/sulbactam sodium intravenous - Shenzhen Salubris Pharmaceuticals
Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Shenzhen Salubris Pharmaceuticals
- Class Antibacterials; Cephalosporins; Penicillins
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory tract infections; Urinary tract infections
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Respiratory-tract-infections in China (IV, Injection)
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Urinary-tract-infections in China (IV, Injection)
- 24 Nov 2015 Clinical trials in Respiratory tract infections in China (IV)